Bogush T A, Dudko E A, Beme A A, Bogush E A, Polotskiĭ B E, Tiuliandin S A, Davydov M I
Antibiot Khimioter. 2009;54(7-8):41-9.
A review of the literature data on expression of estrogen receptor alpha and beta (ERalpha and ERbeta) in tumors different from breast cancer. The results regarding the ERalpha and ERbeta expression frequency in non-small cell and small cell lung cancer, colorectal cancer, esophageal, ovarian, prostate and brain tumors are presented. High frequency of estrogen receptor expression (in up to 50 and more per cent of cases) in various types of tumors, differences between ERalpha and ERbeta in expression frequency, prognostic significance and prediction of the neoplastic process aggressiveness as well as in biological implications of interaction with antiestrogens (antagonistic and/or agonistic effect) are shown. The data on comparative evaluation of ERalpha and ERbeta expression in lung, ovarian, prostate tumor cells and corresponding nonneoplastic tissues are reported. Authors consider necessary to include the ERalpha and ERbeta detection into the routine clinical practice not only in breast cancer but in other tumors as well. Prospects of the clinical application of antiestrogens, in particular tamoxifen, in adjuvant therapy of different tumors with positive ER status are discussed.
一篇关于雌激素受体α和β（ERα和ERβ）在非乳腺癌肿瘤中表达的文献数据综述。展示了非小细胞肺癌、小细胞肺癌、结直肠癌、食管癌、卵巢癌、前列腺癌和脑肿瘤中ERα和ERβ表达频率的结果。显示了各种类型肿瘤中雌激素受体高表达频率（高达50%及以上病例）、ERα和ERβ表达频率差异、肿瘤发生过程侵袭性的预后意义和预测以及与抗雌激素相互作用的生物学意义（拮抗和/或激动作用）。报道了肺、卵巢、前列腺肿瘤细胞及相应非肿瘤组织中ERα和ERβ表达的比较评估数据。作者认为不仅在乳腺癌，而且在其他肿瘤的常规临床实践中纳入ERα和ERβ检测是必要的。讨论了抗雌激素，特别是他莫昔芬，在ER阳性不同肿瘤辅助治疗中的临床应用前景。
